Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging

Abstract

IMPORTANCE Blood biomarkers able to diagnose Alzheimer disease (AD) at the preclinical stage would enable trial enrollment when the disease is potentially reversible. Plasma neuronal-enriched extracellular vesicles (nEVs) of patients with AD were reported to exhibit elevated levels of phosphorylated (p) tau, Aβ42, and phosphorylated insulin receptor substrate 1 (IRS-1). OBJECTIVE To validate nEV biomarkers as AD predictors. DESIGN, SETTING, PARTICIPANTS This case-control study included longitudinal plasma samples from cognitively normal participants in the Baltimore Longitudinal Study of Aging (BLSA) cohort who developed AD up to January 2015 and age-and sex-matched controls who remained cognitively normal over a similar length of follow-up. Repeated samples were blindly analyzed over 1 year from participants with clinical AD and controls from the Johns Hopkins Alzheimer Disease Research Center (JHADRC). Data were collected from September 2016 to January 2018. Analyses were conducted in March 2019. MAIN OUTCOMES AND MEASURES Neuronal-enriched extracellular vesicles were immunoprecipitated; tau, Aβ42, and IRS-1 biomarkers were quantified by immunoassays; and nEV concentration and diameter were determined by nanoparticle tracking analysis. Levels and longitudinal trajectories of nEV biomarkers between participants with future AD and control participants were compared. RESULTS Overall, 887 longitudinal plasma samples from 128 BLSA participants who eventually developed AD and 222 age and sex-matched controls who remained cognitively normal were analyzed. Participants were followed up (from earliest sample to AD symptom onset) for a mean (SD) of 3.5 (2.31) years (range, 0-9.73 years). Overall, 161 participants were included in the training set, and 80 were in the test set. Participants in the BLSA cohort with future AD (mean [SD] age, 79.09 [7.02] years; 68 women [53.13%]) had longitudinally higher p-tau181, p-tau231, pSer312-IRS-1, pY-IRS-1, and nEV diameter than controls (mean [SD] age, 76.2 [7.36] years; 110 women [50.45%]) but had similar Aβ42, total tau, TSG101, and nEV concentration. In the training BLSA set, a model combining preclinical longitudinal data achieved 89.6% area under curve (AUC), 81.8% sensitivity, and 85.8% specificity for predicting AD. The model was validated in the test BLSA set (80% AUC, 55.6% sensitivity, 88.7% specificity). Preclinical levels of nEV xbiomarkers were associated with cognitive performance. In addition, 128 repeated samples over 1 year from 64 JHADRC participants with clinical AD and controls were analyzed. In the JHADRC cohort (35 participants with AD: mean [SD] age, 74.03 [8.73] years; 18 women [51.43%] and 29 controls: mean [SD] age, 72.14 [7.86] years; 23 women [79.31%]), nEV biomarkers achieved discrimination with 98.9% AUC, 100% sensitivity, and 94.7% specificity in the training set and 76.7% AUC, 91.7% sensitivity, and 60% specificity in the test set. CONCLUSIONS AND RELEVANCE We validated nEV biomarker candidates and further demonstrated that their preclinical longitud...

Astrocyte- and neuron-derived extracellular vesicles from Alzheimer’s disease patients effect complement-mediated neurotoxicity

“…EV purification of immunoprecipitated EVs was confirmed by western blots showing enrichment for transmembrane and intravesicular EV markers (i.e. CD81 and alix), low levels of apolipoprotein A1 and absence of the Golgi-specific negative EV marker GM-130, in comparison with EV-depleted plasma and total EVs, as previously seen (27) (Fig. S1c).…”

“…The role of EVs in the brain is multifaceted and includes the exchange of cargo molecules between neurons and glia to regulate neuronal activity (22), but also the transfer of misfolded α-synuclein, A, and hyperphosphorylated tau, possibly contributing to neurodegenerative disease propagation (23,24). We and others have isolated neuronal and astrocytic originenriched EVs (NEVs and AEVs, respectively) from plasma and human cells by particle precipitation followed by immunocapture with anti-GLAST and anti-L1CAM antibodies respectively and have shown that they are carriers of AD pathogenic proteins (25)(26)(27).…”

Low-Density Lipoprotein Cholesterol and Alzheimer's Disease: A Systematic Review and Meta-Analysis

“…Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible decline in cognition (Kapogiannis et al, 2019). It accounts for approximate twothirds of all dementias with an increasing morbidity (Prince et al, 2013) and heavy burden of finance (Reitz and Mayeux, 2014).…”

Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression

“…The majority of studies have used peripheral biomarkers to proxy brain processes, relying on the assumption that peripheral and brain immune activation are correlated (or that peripheral measures are reliable indicators of central processes), which has important limitations. A recent innovation is the use of blood extracellular vesicles (EVs) enriched for neuronal origin (NEVs) as a source of biomarkers that directly reflect neuronal-specific processes [19][20][21][22][23]. Extracellular vesicles (including exosomes) are membranous particles that are continuously released by virtually all cells, including neurons [24].…”

“…Extracellular vesicles (including exosomes) are membranous particles that are continuously released by virtually all cells, including neurons [24]. They can cross the blood-brain barrier and be preferentially isolated from peripheral blood, through immunocapture with antibodies against neuronal markers, most commonly L1 Cell Adhesion Molecule (L1CAM), a procedure that offers a multi-fold enrichment in neuronal cargo [19][20][21][22][23]. Extracellular vesicles contain cargo that reflects the content of the vesicle's cellular origin, providing a novel avenue for probing intracellular signaling processes including neuroinflammatory pathways that are putatively implicated in neuropsychiatric disorders.…”